{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:51:16Z","timestamp":1772077876750,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Secukinumab treatment has previously been shown to significantly improve the signs and symptoms of active ankylosing spondylitis (AS), with responses sustained through 2 years. Here, we report the long-term (3\u2009years) efficacy and safety of secukinumab in the MEASURE 2 study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MEASURE 2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01649375\">NCT01649375<\/jats:ext-link>) is a 5-year phase III, randomised, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of subcutaneous loading and maintenance dosing of secukinumab in adult subjects with active AS. Subjects were randomised to receive subcutaneous secukinumab 150\u2009mg, 75\u2009mg or placebo at baseline, weeks 1, 2 and 3 and every 4 weeks from week 4. At week 16, placebo-treated subjects were rerandomised to receive secukinumab 150\/75\u2009mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Retention rates were high during weeks 16\u2013156 and were 86% and 76% for secukinumab 150 and 75\u2009mg, respectively. Secukinumab 150\u2009mg provided sustained improvements in the Assessment of Spondyloarthritis International Society ASAS 20\/40 response rates at week 156 (70.1%\/60.9%) compared with week 52 (74.2%\/57.0%); however, there was a slight decrease for secukinumab 75\u2009mg (54.3%\/37.0% vs 62.5%\/43.2%, respectively). Sustained improvements were observed in all other end points, including Bath Ankylosing Spondylitis Disease Activity Index, AS Disease Activity Score with C reactive protein inactive disease, ASAS 5\/6, Short Form-36 Physical Component Summary and ASAS partial remission. Clinical benefits were observed regardless of prior exposure to anti-tumour necrosis factor agents. The safety profile remained favourable and was consistent with previous reports.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study showed sustained improvement through 3 years in signs, symptoms and physical function in subjects with AS. Retention rates were high and secukinumab was well tolerated, with a favourable safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2017-000592","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T20:10:14Z","timestamp":1514578214000},"page":"e000592","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":68,"title":["Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2"],"prefix":"10.1136","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct01649375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01649375","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Helena","family":"Marzo-Ortega","sequence":"first","affiliation":[{"name":"Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"University Clinic Benjamin Franklin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Cohen","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evie-Maria","family":"Delicha","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Rohrer","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanno","family":"Richards","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"2025090313380282000_3.2.e000592.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2025090313380282000_3.2.e000592.2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American college of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313380282000_3.2.e000592.3","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.993378"},{"key":"2025090313380282000_3.2.e000592.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"key":"2025090313380282000_3.2.e000592.5","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"2025090313380282000_3.2.e000592.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"2025090313380282000_3.2.e000592.7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nrrheum.2016.7","article-title":"Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis","volume":"12","author":"Duarte","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313380282000_3.2.e000592.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"2025090313380282000_3.2.e000592.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090313380282000_3.2.e000592.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2025090313380282000_3.2.e000592.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090313380282000_3.2.e000592.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090313380282000_3.2.e000592.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"2025090313380282000_3.2.e000592.14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"2025090313380282000_3.2.e000592.15","unstructured":"American college of rheumatology. Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials. Madrid, Spain: EULAR, 2017."},{"key":"2025090313380282000_3.2.e000592.16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090313380282000_3.2.e000592.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090313380282000_3.2.e000592.18","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090313380282000_3.2.e000592.19","unstructured":"Baraliakos X , Kivitz AJ , Deodhar AA , et al . Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 2017."},{"key":"2025090313380282000_3.2.e000592.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"key":"2025090313380282000_3.2.e000592.21","doi-asserted-by":"publisher","DOI":"10.1186\/ar2790"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:38:08Z","timestamp":1756931888000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,12,28]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/rmdopen-2017-000592"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000592","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}